BPC 157 as a Potential Protective Treatment for COVID-19 Vascular Damage
BPC 157's demonstrated anti-inflammatory, cytoprotective, and endothelial-protective properties across animal models suggest potential as a complementary treatment for COVID-19's vascular and multi-organ damage.
Quick Facts
What This Study Found
BPC 157's demonstrated eNOS activation, NO-mediated tissue repair, and angiomodulatory properties in animal models provide a theoretical basis for its use as a complementary treatment for COVID-19's endothelial and multi-organ damage.
Key Numbers
eNOS activation; NO release; endothelial protection; anti-inflammatory; cytoprotective; all from animal models
How They Did This
Medical hypothesis paper reviewing existing animal model evidence for BPC 157's vascular and organ protective effects, applied to COVID-19 pathophysiology.
Why This Research Matters
COVID-19 caused millions of deaths partly through vascular damage and multi-organ failure. Identifying agents that protect the vascular endothelium could improve outcomes and provide treatment options for the vascular complications of this and future pandemic viruses.
The Bigger Picture
BPC 157 has been extensively studied for its healing and protective properties across many organ systems. Applying its known vascular protective mechanisms to COVID-19 pathology represents a logical extension of its documented effects, though human clinical data remains the critical missing piece.
What This Study Doesn't Tell Us
Hypothesis paper based on animal model data — no human COVID-19 clinical trial data. BPC 157 lacks FDA approval and comprehensive human safety data. Theoretical extrapolation from other conditions to COVID-19.
Questions This Raises
- ?Would BPC 157 be effective in human COVID-19 patients?
- ?What dose and timing would be optimal for COVID-19 vascular protection?
- ?Could BPC 157 prevent long COVID vascular complications?
Trust & Context
- Key Stat:
- Multi-organ vascular protection BPC 157's demonstrated eNOS activation and endothelial protection across organ systems in animal models
- Evidence Grade:
- Medical hypothesis based on animal model evidence extrapolated to COVID-19. No clinical trial data available for this specific application.
- Study Age:
- Published in 2021 during the COVID-19 pandemic, proposing a novel therapeutic approach based on existing animal research.
- Original Title:
- BPC 157 as Potential Treatment for COVID-19.
- Published In:
- Medical hypotheses, 158, 110736 (2021)
- Authors:
- Deek, Sarah A
- Database ID:
- RPEP-05337
Evidence Hierarchy
Frequently Asked Questions
Could BPC 157 help with COVID-19?
It's a theoretical possibility. BPC 157 has shown strong vascular and organ protective effects in animal studies. Since COVID-19 primarily damages blood vessel lining cells, BPC 157's endothelial protection could theoretically help. However, no human clinical trials have tested this.
Is BPC 157 approved for treating COVID-19?
No. BPC 157 is not FDA-approved for any condition. This paper proposes it as a potential treatment based on its animal research showing vascular protection, but clinical trials in humans would be needed before it could be used medically for COVID-19 or any other condition.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-05337APA
Deek, Sarah A. (2021). BPC 157 as Potential Treatment for COVID-19.. Medical hypotheses, 158, 110736. https://doi.org/10.1016/j.mehy.2021.110736
MLA
Deek, Sarah A. "BPC 157 as Potential Treatment for COVID-19.." Medical hypotheses, 2021. https://doi.org/10.1016/j.mehy.2021.110736
RethinkPeptides
RethinkPeptides Research Database. "BPC 157 as Potential Treatment for COVID-19." RPEP-05337. Retrieved from https://rethinkpeptides.com/research/deek-2021-bpc-157-as-potential
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.